Alsevalimab is currently study as a experimental therapeutic agent targeting human B7-H4. This immune-modulating treatment exhibits initial effectiveness in multiple malignant forms by blocking B7-H4's role in tumor progression and host suppression. Future research trials aim to evaluate this tre